A blog about chemistry, drug development, science, and technology
Pages (999999): [1] 2 3 » ... Last »
Tuberculosis (TB) has been making a come back for a long time. Although it has been practically wiped out in the Western world it is still fairly prevalent in other parts of the world. Now it seems there is a strain that can not be treated by the commonly used prescription drugs.
TB strain identified as ‘virtually untreatable’
There are over 425,000 cases of multi-drug resistant (MRT) TB each years world-wide mostly in India, China and the former Soviet Union. The resistance develops primarily because treatment isn’t followed through completely.
Also, TB isn’t the only bacteria developing resistance. many common bacteria are now occurring that are resistant to many common anti-biotics and the number of drugs to treat these is not increasing at a equivalent pace.
The main problem is these drugs don’t generate huge financial numbers for big pharma and something is going to have to change before advances are made. Maybe once it again becomes a common problem like it was back in the early 20th century will there again be a resurgence in discovery activities related to antibiotics.
Other Resources
• WHO | Tuberculosis
• Center for Disease Control | Tuberculosis
• MedlinePlus: Tuberculosis
• Tuberculosis - Wikipedia, the free encyclopedia
Technorati Tags: antibiotics, drug resistance, tuberculosis
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
Adeza has a new drug to help prevent premature births and is seen is a promising drug as reported by Forbes.
Adeza Shares Seen As Attractive Following FDA News - Forbes.com:
The article covers that the Reproductive Health Drugs Advisory Committee has recommended for approval Gestiva indicated to prevent premature births. Premature births occur much more frequently now than in past years mainly due to advancements made in fertility treatments; currently about 12% of all births are premature (less than 37 weeks gestation). Also, premature births tend to be very costly to the health care system. According to this site March of Dimes put the cost in 2003 of $11 billion for preterm birth.
Further Resources
• Press Release from Adeza on FDA recommendation for approval
• Adezas Gestiva recommended for FDA approval - Pharmaceutical Business Review
• FDA questions effectiveness of Gestiva at preventing preterm labor
Technorati Tags: Gestiva, premature birth, Adeza
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
Pages (999999): [1] 2 3 » ... Last »
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

40 queries. 0.992 seconds